Casgevy (Exagamglogene Autotemcel)

Casgevy is a one-time gene-editing treatment for sickle cell disease and a blood disorder called beta-thalassemia. Doctors collect a person's own blood stem cells, edit them in a lab, and give them back as an infusion into a vein. The edited cells make a kind of hemoglobin that helps red blood cells work properly.

Brand names:Casgevy
Medication

What people taking Casgevy (Exagamglogene Autotemcel) report

Every report comes from a Lived member, sent anonymously.

Have you tried Casgevy (Exagamglogene Autotemcel) for Sickle Cell Disease?

NameHow it went

About Casgevy (Exagamglogene Autotemcel)

What It's For

Casgevy (exagamglogene autotemcel) is a one-time gene therapy made from a person's own blood-forming stem cells. In the US it is approved for people aged 2 and older with sickle cell disease who keep having vaso-occlusive crises, the severe pain episodes that happen when sickled red blood cells block small blood vessels. It is also approved for people aged 2 and older with transfusion-dependent beta-thalassemia, an inherited anemia severe enough to need regular red blood cell transfusions. Casgevy was the first FDA-approved treatment to use CRISPR, a gene-editing technology. It is not a pill or a routine infusion: it is given as part of a stem cell transplant that uses high-dose chemotherapy, so it is offered at specialized treatment centers to people whose disease is serious enough to justify that process. The studies behind it included people aged 5 and older; use in children aged 2 to 4 is based on extrapolating those results. Other options that a hematology team may discuss include a donor stem cell transplant and other gene therapies, such as Lyfgenia for sickle cell disease in people 12 and older and Zynteglo for beta-thalassemia.

How It Works

Hemoglobin is the protein in red blood cells that carries oxygen. In sickle cell disease, the adult form of hemoglobin is faulty and makes red blood cells stiff and crescent-shaped. In beta-thalassemia, the body cannot make enough of a key part of adult hemoglobin, so red blood cells are too few and do not work well. Both conditions start in stem cells in the bone marrow that produce red blood cells. The body can also make fetal hemoglobin, the form used before birth, which carries oxygen well and does not sickle. The body largely switches over to the adult form, and a gene called BCL11A helps keep fetal hemoglobin turned down. For Casgevy, a person's stem cells are collected and, in a laboratory, CRISPR makes a precise cut in the stretch of DNA that switches BCL11A on in red-cell-producing cells. With BCL11A turned down, the new red blood cells make more fetal hemoglobin. After chemotherapy clears space in the bone marrow, the edited cells are infused and settle there (a process called engraftment). In sickle cell disease, the extra fetal hemoglobin dilutes the faulty hemoglobin and keeps red cells from sickling. In beta-thalassemia, it raises total hemoglobin so the body no longer depends on transfusions.

Dosage & Administration

Treatment happens in stages over several months, coordinated by a transplant center. First, people usually receive regular red blood cell transfusions for at least about two months, and some usual medicines are stopped. Stem cells are then moved from the bone marrow into the bloodstream with injected medicines and collected through apheresis, a process similar to a long blood donation in which a machine separates out the stem cells. Some people need two or more collection cycles, spaced at least two weeks apart, and in the sickle cell studies about 1 in 10 people who started collection could not be treated because not enough cells could be gathered. Extra unedited stem cells are also stored as a back-up. Once the edited cells are made and shipped, the person is admitted for myeloablative conditioning, high-dose chemotherapy (usually busulfan) given over four days through a central line to clear out the existing bone marrow. Between two and seven days later, Casgevy is given as a one-time intravenous infusion, usually after medicines to prevent fever and allergic reactions. The dose is based on body weight and is prepared for that individual person only. Because the cells are the person's own, anti-rejection medicines are not needed afterward.

Side Effects

Most of the hard part of treatment comes from the chemotherapy. In the weeks after the infusion, blood counts drop to very low levels in everyone until the new cells start working. Painful mouth and throat sores, poor appetite, nausea and fever with low white blood cell counts (which often signals infection) were common in the studies, and serious side effects occurred in about a third to nearly half of people. People are watched closely and treated for infection during this time. Platelets, the cells that help blood clot, can take weeks or months to recover, so bleeding risk stays higher during that period. New or worsening bleeding or bruising should be reported to the transplant team right away. Busulfan can also cause veno-occlusive disease, in which small blood vessels in the liver become blocked; it was among the more frequent serious reactions in the beta-thalassemia studies, and one child with beta-thalassemia died after this and other complications. Allergic reactions to the freezing solution in the infusion, including anaphylaxis, are possible, which is why the infusion is closely monitored. Infertility is a known effect of the chemotherapy and is discussed below.

Interactions & Warnings

Several sickle cell and thalassemia treatments have to be paused. Hydroxyurea and crizanlizumab (Adakveo, an infusion that reduces how often sickle cell pain crises happen) are stopped at least eight weeks before stem cell collection and chemotherapy. Iron chelators, the medicines that remove excess iron built up from transfusions, are stopped at least a week before chemotherapy and avoided for at least three to six months afterward, depending on the type; removing blood (phlebotomy) can be used instead if iron needs to be lowered. Safety of live vaccines during or after treatment has not been studied, so vaccine timing should be planned with the team. The chemotherapy can cause permanent infertility, so fertility preservation, such as freezing eggs, sperm or tissue, is worth discussing before treatment starts. Casgevy must not be given during pregnancy. A pregnancy test is required before each collection cycle and again before chemotherapy, and both women and men should use effective contraception from the start of stem cell collection until at least six months after the infusion. People with active HIV, hepatitis B or hepatitis C cannot receive it. Anyone treated should never donate blood, organs, tissues or cells in the future. The editing could in theory make unintended changes elsewhere in a person's DNA, and the long-term importance of that possibility is not yet known.

What to Expect

Recovery after the infusion is measured in weeks. In the studies, infection-fighting white blood cells (neutrophils) recovered at a median of about four weeks, and platelets at a median of roughly five to seven weeks, though some people took several months. Frequent blood tests track this, and transfusions may still be needed for a few weeks. If the new cells failed to take hold, the stored back-up cells would be given; this did not happen to anyone in the studies. The benefits shown so far are large but based on small studies without a comparison group. Among adults and teens with sickle cell disease, 29 of 31 people went at least a year without a severe pain crisis. Among those with beta-thalassemia, 32 of 35 went at least a year without needing a transfusion, and the remaining three needed far fewer. Results in children aged 5 to 11 were similar. Not every person responds this way, and organ damage that happened before treatment does not necessarily reverse. Because Casgevy has been available only since 2023, how long the benefit lasts and its long-term safety are still being studied. Study participants are followed for 15 years, and ongoing follow-up with a hematology team is part of treatment.

Questions to Ask Your Doctor

  1. 1.Is my disease severe enough that Casgevy's benefits outweigh the risks of high-dose chemotherapy, and how does it compare with a donor transplant or another gene therapy for me?
  2. 2.How long will the whole process take, from transfusions and stem cell collection to recovery, and how long will I need to stay in or near the treatment center?
  3. 3.What are my options for preserving fertility before chemotherapy, and is there time to do that?
  4. 4.Which of my current medicines, including hydroxyurea and iron chelation, will need to stop, and what will replace them in the meantime?
  5. 5.What follow-up will I need in the years after treatment, and what results would show it is working?

Last reviewed • Oct 2026

Educational content, not medical advice.